Baker & McKenzie advised Arrow Pharmaceuticals Limited on its merger with Sigma Company Limited, to form a $2.2 billion firm, Sigma Pharmaceuticals. Guy Sanderson and Astrid Raetze led Bakers’ team.
Sanderson said the transaction was one of the biggest public company mergers this year and would create a substantial Australian pharmaceutical business.
“We have built a strong relationship with Arrow since advising them on their successful ASX listing in October 2002,” he said. “Our understanding of Arrow’s operations allowed us to negotiate, as part of the merger, a Shareholders Deed between Sigma and Arrow’s founding shareholders.
Sanderson said the transaction contained a novel combination of sell-down, standstill, orderly marketing and voting provisions, which required an application for relief to be made to ASIC for the merger to proceed.
“The value we brought, beyond our detailed knowledge of Arrow’s business, was our global pharmaceutical practice which gave us a depth of knowledge and expertise to address issues peculiar to pharmaceutical companies.”
Mallesons Stephen Jaques acted for Sigma Company.